Mentioned:
HIMS -6.50% LLY +0.65%

Weight loss drugs continue to be in high demand. And now, Novo Nordisk is partnering with one of the fastest growing healthcare companies America to expand their distribution.

‍What’s happening:‍

  • Hims & Hers Health (NYSE: HIMS) has formed a new partnership with Novo Nordisk (NYSE: NVO) to expand accessibility to weight loss drugs and provide clinical support to individuals seeking to lose weight

How it works:‍

  • For a reoccurring monthly fee patients can now access Novo Nordisk’s Wegovy medication, ongoing clinical support, nutrition guidance and access to healthcare providers through the Hims & Hers Health telemedicine platform
  • Users of Hims & Hers Health can also access Novo Nordisk’s NovoCare Pharmacy directly through the Hims & Hers Health telemedicine platform and have their Wegovy prescription sent directly to their residence

Why it matters:‍

  • This is the first time that Novo Nordisk has struck a partnership with a telemedicine platform for expanding accessibility of their highly popular Wegovy GLP-1 weight loss drug

Going deeper:‍

  • Novo Nordisk has also cut other new telemedicine partnerships for Wegovy distribution beyond their deal with Hims & Hers Health, including striking deals with LifeMD and Ro
  • Novo Nordisk and Hims & Hers Health have both publicly stated that they plan to roll out more products and healthcare support for patients as part of their long term partnership, including expanding into the treatment of chronic diseases

The intrigue:‍

‍